Two doses of BNT162b2 SARS-CoV-2 vaccine highly effective

New antibody rationally designed for better tumor inhibition
7 May 2021
EU sceptical of US push to lift COVID vaccine patents
7 May 2021

Two doses of BNT162b2 SARS-CoV-2 vaccine highly effective

Two doses of BNT162b2 are highly effective for preventing symptomatic and asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and other outcomes, according to a study published online May 5 in The Lancet.

Comments are closed.